Prospect Capital books $328 million exit, gives PSEC stock a new driver
Prospect Capital shares rose 2.1% to $2.37 after announcing the sale of Valley Electric to MYR
Horizon Technology Finance Stock Jumps Before the Open — Why the Dividend Math Matters Now
Horizon Technology Finance Corp shares rose 1.9% to $4.27 in early premarket Nasdaq trading Friday, following a 2.7% gain Thursday. No new company filings or press releases appeared in the past two
Newell Brands Stock Just Slid Again — Why the Sharpie Maker’s Turnaround Is Being Tested
Newell Brands shares fell about 4% Thursday afternoon to $3.515, underperforming broad U.S. market gains. The drop follows a brief rebound and comes ahead of Friday’s dividend record date. Investors remain cautious despite a raised 2026 outlook, citing weak sales, high debt, and unresolved tariff refunds. Trading volume stayed below average as the stock continued to lag sector peers.
Solid Power Shares on the Move Again; Battery Bulls Eye $3.40
Solid Power shares traded at $3.40, up 1.2% Thursday afternoon on the Nasdaq, with volume near 4 million and market cap around $739 million. Investors watched updates on SK On work and cash position, as the company reported $3.1 million in Q1 revenue and $435.3 million in liquidity. Peers QuantumScape and SES AI also rose. Solid Power focuses on selling solid electrolyte material and licensing its battery tech.
Viking Therapeutics Stock Draws Wall Street Attention with Obesity Pill Competition Growing
Viking Therapeutics shares rose 1.7% to $32.19 after Lake Street initiated coverage with a Buy rating and an $89 price target, citing potential for its obesity drug VK2735. Phase 2 trial data showed up to 12.2% mean weight loss in 13 weeks. The company’s market cap stood at $3.72 billion. Board elections and auditor approval were disclosed in a May 26 SEC filing.
MapLight Stock Slips Ahead of August Drug Update
MapLight Therapeutics shares fell 1.3% to $29.17 Thursday as investors awaited Phase 2 trial results for schizophrenia and autism, expected by mid-August. The company finished enrolling 307 patients in its ZEPHYR schizophrenia study and ended March with $395.2 million in cash. Analyst price targets ranged from $28 to $48. MapLight’s lead drug targets muscarinic receptors, a newer approach in antipsychotic treatment.
Peraso Stock Pops 13% as PRSO Traders Bet a Delayed Order Is Finally Behind It
Peraso Inc. shares rose about 13% Thursday, trading near $1.165 on volume of 1.29 million after closing at $1.03. The move followed weak first-quarter results, with net revenue down to $963,000 from $3.87 million a year earlier and a net loss widening to $2.5 million. Management said a delayed customer order has now shipped. No new company disclosures were issued Thursday.
New Fortress Energy Shares Dip Under 60 Cents Ahead of Key Reverse-Split Vote
New Fortress Energy Inc. fell to 55.79 cents early Thursday, down 3.8%, with a market value near $159 million after releasing its annual meeting proxy. The company faces possible Nasdaq delisting after months below $1 per share and reported a Q1 net loss of $399.95 million on $226.95 million revenue. Debt stood at $8.29 billion as of March 31, with most classified as current due to defaults. Shareholders will vote June 17 on a 1-for-50 reverse split and restructuring plan.
Big Digital Energy Stock Drops as Its AI-Power Pivot Runs Into a Cash Test
Big Digital Energy Inc. shares fell 20 cents to $6.46 in Nasdaq trading Thursday, underperforming larger bitcoin-mining peers. The company reported Q1 revenue dropped to $4.8 million from $13.8 million a year earlier, with operations losing $8.2 million and cash use of $17.1 million. Big Digital ended March with $2.4 million in cash and warned of “substantial doubt” about its ability to continue as a going concern.
Satellogic stock pops on $18 million injection, 10 million-share filing appears
Satellogic Inc. rose 1.6% to $9.93 Thursday after announcing an $18 million, one-year defense contract and a major shareholder’s plan to sell 10 million shares. The stock traded between $9.47 and $10.11, with market cap near $1.40 billion. First-quarter revenue climbed 80% to $6.1 million, and the company reported positive operating cash flow. Liberty Strategic Capital filed notice to sell shares worth $97.7 million.
New Fortress Energy Shares Dip Under 60 Cents Ahead of Key Reverse-Split Vote
New Fortress Energy Inc. fell to 55.79 cents early Thursday, down 3.8%, with a market value near $159 million after releasing its annual meeting proxy. The company faces possible Nasdaq delisting after months below $1 per share and reported a Q1 net loss of $399.95 million on $226.95 million revenue. Debt stood at $8.29 billion as of March 31, with most classified as current due to defaults. Shareholders will vote June 17 on a 1-for-50 reverse split and restructuring plan.
Big Digital Energy Stock Drops as Its AI-Power Pivot Runs Into a Cash Test
Big Digital Energy Inc. shares fell 20 cents to $6.46 in Nasdaq trading Thursday, underperforming larger bitcoin-mining peers. The company reported Q1 revenue dropped to $4.8 million from $13.8 million a year earlier, with operations losing $8.2 million and cash use of $17.1 million. Big Digital ended March with $2.4 million in cash and warned of “substantial doubt” about its ability to continue as a going concern.
Satellogic stock pops on $18 million injection, 10 million-share filing appears
Satellogic Inc. rose 1.6% to $9.93 Thursday after announcing an $18 million, one-year defense contract and a major shareholder’s plan to sell 10 million shares. The stock traded between $9.47 and $10.11, with market cap near $1.40 billion. First-quarter revenue climbed 80% to $6.1 million, and the company reported positive operating cash flow. Liberty Strategic Capital filed notice to sell shares worth $97.7 million.
Moderna Shares Dip With FDA Vote Putting COVID Vaccine Plan to Test
Moderna shares fell 2.6% to $46.39 Thursday as an FDA advisory panel met to discuss the 2026-2027 COVID-19 vaccine formula, focusing on the XFG strain. The company reported a Q1 net loss of $1.3 billion and $389 million in revenue, mostly outside the U.S. FDA advisers will review Moderna’s mRNA flu shot for older adults on June 18. Wall Street analysts remain divided on the stock’s outlook.
Xerox pops after 15 million-share filing seen as turnaround signal
C4 Therapeutics shares traded at $3.74 before the Nasdaq open on May 28, holding gains after a 7.16% rise the prior session. The move comes as investors await cemsidomide updates at ASCO and EHA meetings. C4 reported $268.3 million in cash at March 31 and a narrowed Q1 net loss. The company expanded its Roche partnership in April, securing a $20 million upfront payment.
NewAmsterdam Pharma Stock Rises as Fresh Filing Puts Its $4.3 Billion Drug Bet in Focus
NewAmsterdam Pharma shares rose 1.3% to $36.56 Wednesday after Chief Accounting Officer Louise Frederika Kooij exercised and sold 65,000 shares, according to a Form 4 filing. A separate Form 144 listed a proposed sale of 210,000 shares for Kooij. The company awaits key regulatory decisions on its cholesterol drug obicetrapib later this year. NewAmsterdam reported a first-quarter net loss of $48.4 million.
Eva Live Stock Falls As $20 Million AI Senior-Care Bet Runs Into Cash Questions
Eva Live shares fell 3.4% to $3.275 in early Nasdaq trading Friday after the company announced a preliminary deal to invest up to $20 million for a 25% stake in Spiro Senior Care. The company reported a first-quarter net loss of $8.6 million on $3.9 million revenue. Trading volume reached 43,221 shares, with a market value near $118 million. Wall Street indexes opened higher.
ARKO Dips on Dividend Day as Fuel Margins Draw Scrutiny
Arko Corp. shares fell 4 cents to $7.79 Friday as its $0.03 dividend became payable and investors weighed first-quarter results showing a narrowed net loss of $5.6 million and 65% higher adjusted EBITDA. The company has converted 450 stores to wholesale, nearing its 500-store goal. ARKO Petroleum, spun off in February, rose nearly 1% to $19.30. Market cap for Arko stood at about $867 million.
Stock Yards Bancorp Shares Gain; Investors Eye October Field & Main Deadline
Stock Yards Bancorp shares rose 0.3% to $71.51 Friday morning, bucking weakness in regional banks as investors watched for updates on its Field & Main Bancorp integration. The company completed the Field & Main takeover May 1 and aims to finish system integration by Oct. 17. First-quarter net income rose to $36.6 million from $33.3 million a year earlier. The board approved a $0.32 dividend, payable July 1.
Nasdaq Deadline Looms After Empro Stock Halted
Empro Group Inc. shares remained halted on Nasdaq Friday after the company failed to file its 2025 annual report, triggering a compliance notice. The halt began in October 2025 for “news pending” and follows an SEC suspension over suspected social media-driven manipulation. Empro went public in July 2025 at $4 per share. The last recorded price before the halt was $17.36, but that figure is outdated.
MindWalk Stock Slips as AI Pandemic Platform Launch Puts HYFT Back in Focus
MindWalk Holdings traded at $1.77, down 1.1% in early Nasdaq action Friday on thin volume after announcing a pandemic-response platform built on HYFT and LensAI technology. The company reported no new revenue, contracts, or clinical data tied to the launch. The move comes as health agencies monitor Ebola and hantavirus outbreaks. Investors showed caution, with rival AI-biotech stocks also mixed.
Prospect Capital books $328 million exit, gives PSEC stock a new driver
Prospect Capital shares rose 2.1% to $2.37 after announcing the sale of Valley Electric to MYR Group for about $328 million. Prospect expects net exit proceeds of $280 million, or 9.5% of its March 31 net asset value. The stock remains below NAV, reflecting investor concerns despite the sale. MYR plans to fund the purchase with cash and credit.
Cheetah Net Stock Slips Before the Open. The Real CTNT Test Is Bigger Than Today’s Price Move
Cheetah Net Supply Chain Service Inc. shares traded at $1.61 premarket Friday, down 3 cents, after weak first-quarter revenue and a recent one-for-200 reverse stock split. The company reported $92,700 in logistics and warehousing revenue, down 80.7% year-over-year, and a narrowed net loss of $616,265. No new company news was released in the past 48 hours.
Yunji Stock Near $1.57: Tiny Nasdaq China E-Commerce Bet Faces a Bigger Test
Yunji Inc.’s U.S.-traded shares rose 1.3% to $1.57 in thin premarket trading Wednesday, with volume near 1,500 and a market value around $7.7 million. The company last reported a 2025 net loss of RMB133.3 million on revenue of RMB317.0 million, both worse than a year earlier. No new announcements were posted. The stock remains within a 52-week range of $1.11 to $2.67.
Harte Hanks Stock at $2.58: Why This Tiny Nasdaq Name Is Back on Traders’ Screens
Harte Hanks shares traded near $2.58 early Friday after closing down 2.3% on low volume. The company reported a first-quarter net loss of $0.6 million and a 10.3% drop in revenue to $37.3 million. Fulfillment & Logistics revenue fell 16.6% on customer reductions. Harte Hanks ended March with $4.5 million in cash and no borrowings.
Interactive Brokers Reports $871 Billion Client Assets
Interactive Brokers stock rose 2.7% to $83.11 Thursday before Nasdaq’s open, then held steady in Friday premarket trading. April client equity surged 48% to $870.9 billion, with margin loan balances up 57% to $91.3 billion. The broker reported 4.241 million daily average revenue trades, up 11% from last year.
Capital City Bank Slides on Insider Sale, Dividend Date News
Capital City Bank Group shares closed at $46.03, down 1.1%, with premarket trading flat Friday. Treasurer Thomas A. Barron sold 6,000 shares on May 26 at prices between $46.07 and $46.79, leaving him with 147,979 shares. The bank set a $0.27 per share dividend for holders as of June 1, payable June 15. First-quarter net income was $15.8 million, up from the prior quarter but below last year.
Rallybio Stock Faces a $50 Million Test as Traders Weigh What Comes Next
Rallybio shares last traded at $14.52, holding steady after receiving a $50 million break fee from Candid Therapeutics’ canceled merger. The payment now accounts for about two-thirds of Rallybio’s equity value. No new company news has moved the stock, and its lead drug candidate remains far from approval. Trading volume Thursday was 21,282 shares.
McKinley Acquisition Stock Flat at $10 as $176.7M Deal Waits
McKinley Acquisition Corp. closed at $10.19 on May 28, near its trust value, with no merger target identified and $176.7 million in cash held as of March 31. The SPAC reported $1.29 million in quarterly net income, all from interest, and faces a Feb. 13, 2027, deadline to complete a deal or return funds.
iSpecimen trades near lows as cash test and vote loom
iSpecimen shares fell 1.1% in pre-market trading Friday to $3.284, near record lows after a 1-for-40 reverse split. The company scheduled its delayed annual meeting for May 29 as investors watched weak cash and revenue figures. iSpecimen raised $2.5 million in a private placement this month, but cash reserves dropped to $2.82 million at March 31. Management cited “substantial doubt” about its ability to continue as a going concern.
Atlas Critical Minerals Stock Faces a New Test as Defense-Metals Money Rushes Into Nasdaq
Atlas Critical Minerals Corp’s U.S. shares closed Thursday at $4.41, near a 52-week low, with after-hours trading at $4.36. The company raised about $11 million in its January Nasdaq debut, controlling over 218,000 hectares of mineral rights in Brazil. Market value stands at $21.8 million, with thin trading and sparse analyst coverage. Atlas warns of potential volatility and future capital needs in its prospectus.
AEP Falls Again as Investors Scrutinize $78 Billion Grid Spending
American Electric Power closed down 1.4% at $127.76 Thursday, underperforming other major utilities and marking its third straight decline. Shares are 8.4% below their May 5 peak after a surge tied to data-center demand and a $6 billion capital plan increase. Trading volume was above average. Traders are watching cost protections and the impact of recent equity raises.
PTLE stock sits close to $5 ahead of market open as small fuel name hits radar
PTL Ltd shares traded at $5.01 in light pre-market activity Friday, with a market cap near $31.5 million and about 4,000 shares changing hands. The marine-fuel logistics company reported 2025 revenue down 27% to $71.65 million and a narrowed net loss of $1.18 million. PTL recently completed a 1-for-80 reverse split and regained Nasdaq compliance. Cash reserves fell to $1.09 million.
Imperii Acquisition hovers at $10 as SPAC traders turn their focus back
FG Imperii Acquisition Corp shares rose 2 cents to $9.92 in premarket Nasdaq trading Friday. The SPAC reported $229.0 million in its trust account as of March 31 and no operating revenue. Its IPO price was $10 per unit in January, with shares and warrants trading separately since March. The company has 24 months from IPO closing to complete a merger or must return funds to shareholders.
Golden Sun Faces Nasdaq 42-Cent Deadline as Traders Watch
Golden Sun Technology Group Ltd shares rose about 2.3% to $0.418 in premarket indications Friday, still below Nasdaq’s $1 minimum bid requirement. The company faces possible delisting if it fails to lift its closing price above $1 for 10 consecutive days by Oct. 12. Golden Sun reported a 483% jump in fiscal 2025 revenue to $35.5 million, but net loss widened to $5.2 million. The firm cited “substantial doubt” about its ability to continue operating.
Lovesac Stock Back in Focus as Next Test Approaches
Lovesac shares closed up 1.0% at $16.11 Thursday after the company set June 11 for its fiscal first-quarter results. The company projects Q1 net sales of $133–$139 million and an adjusted EBITDA loss of $12–$16 million. Last year’s net income fell to $4.1 million from $11.6 million as margins shrank on tariffs and higher costs. Production has shifted out of China to reduce tariff exposure.